Roth Capital Bumps PT on Ligand Pharma (LGND) up to $149; Says Running on All Cylinders

August 4, 2016 2:27 PM

Roth Capital lifts its price target on Buy-rated Ligand Pharma (Nasdaq: LGND) from $147 to $149 following Q2 results reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found